Lectureship Awards

About Us_Lectureships_Banner

2020 LECTURESHIP AWARD WINNERS

Image
Enrico Ruffini

Enrico Ruffini, MD

Full Professor, Department of Thoracic Surgery, University of Torino, Italy
Italy

Clifton F. Mountain Lectureship Award for Staging 

Image
Samina Park

Samina Park, PhD

Clinical Assistant Professor; Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine

Tsuguo Naruke Lectureship Award for Surgery 

Image
Eric Lim

Eric Lim  MB, ChB, MD, MSc, FRCS(C-Th)

Consultant Thoracic Surgeon, Royal Brompton Hospital; Professor of Thoracic Surgery, Imperial College London

Robert J. Ginsberg Lectureship Award for Surgery 

Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London. He received his undergraduate medical education at the University of Sheffield Medical School. His specialist heart and lung surgical training was at Papworth Hospital in Cambridge and the Royal Brompton Hospital in London. He spent time in medical research in Cambridge where he was awarded a Doctorate of Medicine and in research methods London where he received his Masters of Science in Medical Statistics funded by a UK Medical Research Council Scholarship.

Professor Lim is a sub-specialist in Thoracic Surgery with specific expertise in lung and other chest cancers. His technical expertise is minimally invasive (keyhole) surgery for lung cancer, pleural effusion, pneumothorax and other chest cancers, as well as complex surgery for advanced lung cancer involving airway and blood vessel reconstruction (to save as much normal lung as possible). 

He is the national chair for thoracic academia with an active interest in clinical trials serving as Chief Investigator for UK wide National Institute of Healthcare Research funded multicentre trials of surgery for mesothelioma (MARS 2) and VATS lobectomy (VIOLET). His translational research interest is focused on blood-based cancer diagnosis aspiring to shorten time to diagnosis and eliminate complications of invasive tissue biopsy.

His research has led to over 100 peer review publications, he has authored two award winning textbooks (Medicine and Surgery, Churchill’s Pocketbook of Differential Diagnosis) and 6 book chapters. Professor Lim chaired the British Thoracic Society and Society for Cardiothoracic Surgery’s Guidelines on the Management of Lung Cancer in 2010, contributed to the European Society of Medical Oncology Early Stage Lung Cancer Guidelines in 2013 and European Neuroendocrine Tumours Management of Bronchopulmonary Carcinoids Guidelines in 2014.

He also the Chair of the UK Thoracic Surgery Research Collaborative and served as a Councillor of the European Society of Thoracic Surgeons, a member of the Steering Committee of the British Thoracic Oncology Group, an Associate Editor of Thorax and the Deputy Statistics Editor for the Journal of Thoracic and Cardiovascular Surgery.
 

Image
Mary Duffy

Mary Duffy, RSCN, RGN, RSM

Clinical Nurse Consultant/Lung Cancer Specialist
Australia

IASLC Lectureship Award for Nurses and Allied Health Professionals 

Mary Duffy is the Advanced Practice Clinical Nurse Consultant  for the Lung Service at the Peter Mac Callum Cancer Centre and works primarily with patients who have lung cancer or mesothelioma, and their families.
 
Mary has worked with lung cancer patients for over 20 years in a variety of roles. Her areas of professional   interest include all aspects of supportive care for people with lung cancer and mesothelioma, including symptom management, advocacy, patient and carer information and support.
 
Mary has completed a Masters of Philosophy by Nursing Research at The University of Melbourne. She is an active member of, both national and international, nursing and lung cancer professional organisations and is the inaugural Chairperson of the Australia and New Zealand Lung Cancer Nurses Forum (ANZ-LCNF).
 

Image
Wanda de Kanter Koppenol

Wanda de Kanter-Koppenol, MSc

Chest physician Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Netherlands

IASLC Lectureship Award for Tobacco Control and Smoking Cessation 

Dr. de Kanter-Koppenol a lung specialist mainly working in the lung cancer field as an oncologist and as a patient advocate (consultant lung cancer organization for many years) 

She is also a “preventionist” who is trained in motivational interviewing and founded the biggest smoking cessation clinic in the Netherlands. She is a member of the Smoke free Generation Network.

She is also an activist: primary prevention is crucial: because the nicotine addiction is severe, most people die due to a smoking related disease before then can quit or they quit to late.  She focuses on the tobacco industry lobby in The Hague, politicians and on the tobacco industry itself by lawsuits, (inter) national lectures and ( social) media. They are part of the smoke free generation network: creating smoke free hospitals and all other health departments, including the addiction and psychiatry care. 

Their main focus is tax increase and a decrease in points of sale. Recently this was settled: in 2024 supermarkets are not allowed anymore to sell cigarettes.
 

Image
Sanja Dacic, MD, PhD

Sanja Dacic, MD, PhD

Professor of pathology in the Department of Pathology at the University of Pittsburgh , Director of Anatomic Pathology at UPMC Presbyterian Hospital and Director of Thoracic Pathology Center of Excellence
United States

Fred R. Hirsch Lectureship Award for Translational Research (inaugural year) 

Sanja Dacic, MD, PhD, is a professor of pathology in the Department of Pathology at the University of Pittsburgh , Director of Anatomic Pathology at UPMC Presbyterian Hospital and Director of Thoracic Pathology  Center of Excellence . Dr Dacic received her medical degree and a doctor of philosophy degree at the School of Medicine, University of Zagreb, in Zagreb, Croatia. She completed her residency training at the University of Pittsburgh and joined the faculty immediately after her fellowship in surgical pathology. Dr. Dacic is focused on diagnostic pulmonary and molecular pathology and has been involved in many basic and translational research projects in lung cancer and pleural mesotheliomas that have resulted in numerous peer-reviewed scientific articles, book chapters, and reviews.  She was a co-author of the original and revised CAP/IASLC/ AMP guidelines for molecular testing in lung cancer. Dr. Dacic is a member of the Editorial Board for the upcoming  5th WHO Classification of Thoracic Tumors. She is a deputy editor in chief of Archives of Pathology & Laboratory Medicine

She was elected to the Board of the United States and Canadian Academy of Pathology (USCAP)  for three years (2015-2018) . She has been an officer of the Pulmonary Pathology Society since 2006 and is currently serving as president. Dr. Dacic is a member of the US and Canadian Mesothelioma Group and the  International Mesothelioma Panel. She has been a member of the IASLC Pathology Committee since 2010. Dr. Dacic contributed to the last seven WCLC meeting, including as invited faculty. 
 

Image
Walter John Curran, Jr., M.D.

Walter John Curran, Jr., M.D.

NRG Oncology Presiding Chairman
United States

James D. Cox Lectureship Award for Radiation Oncology 

For the past several decades, Dr. Curran has focused on the conduct of clinical and translational cancer research at the institutional and national cooperative or network group level. He has served as Executive Director of Winship Cancer Institute (Winship) since 2009 and has successfully led Winship to align its cancer care and cancer prevention efforts with its research and education programs, all with the mission of lessening the cancer burden in the state of Georgia. Winship was approved as the latest NCI-designated comprehensive cancer center effective April 1, 2017.

He has also had the great honor to also serve as one of the founding leaders of NRG Oncology, which began its activities as an NCI-supported NCTN network group in 2014. NRG Oncology seeks to improve the duration and quality of lives of adults with non-hematologic malignancies through the conduct of science-driven, NCI-supported multi-institutional clinical trials. His role as an NRG Oncology leader provides an opportunity to integrate outstanding science of cancer investigators everywhere with the national and international reach of a large NCI-supported network group. NRG Oncology focuses on patients with malignancies which disproportionately affect minority patients, and these include the gender-specific malignancies of gynecologic, prostate, or breast cancers as well as brain tumors or head and neck, lung, or gastrointestinal cancers. In its first five years of activity, NRG Oncology has been extraordinarily productive in terms of publications, clinical trial activation and enrollment, and influence on practice standards. His role as one of the three NRG Oncology Group Chairmen requires a highly collaborative interaction with the NRG Oncology investigators, and he looks forward with great anticipation to working with Drs Jordan and his colleagues on projects involving the resources of the NRG Oncology Biospecimen Resources and the NRG Oncology research themes.

Image
Lauren Byers

Lauren Averett Byers, MD

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
United States

Heine H. Hansen Lectureship Award for Small Cell Lung Cancer 

Lauren Averett Byers, MD, MS is an Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology and an Andrew Sabin Family Fellow at MD Anderson Cancer Center in Houston, Texas.  She completed her B.A. degree in Molecular Biology at Princeton University, her M.D. at Baylor College of Medicine, and M.S. in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences.  She is a member of the National Cancer Institute’s Small Cell Lung Cancer (SCLC) Consortium and serves on the NCI’s Thoracic Malignancy Steering Committee and SCLC Working Group. 

Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers, particularly as they pertain to drugs targeting DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer. In addition to an outstanding publication record of over 100 peer reviewed manuscripts, Dr. Byers has earned multiple honors including two AACR The Best of AACR Journals Awards and the MD Anderson President’s Recognition for Faculty Excellence - Research Excellence Award.

As a physician-scientist, her landmark research led to the identification of fundamental differences in the molecular wiring of SCLC, including the identification of PARP1 and other DNA damage repair (DDR) proteins as novel therapeutic targets for SCLC.  Building on this, her group also identified a new role of DDR inhibitors in activating the innate immune system, whereby dramatically enhancing response to immune checkpoint blockade in preclinical models.  Recently, her team has defined molecularly distinct subtypes of SCLC that predict response to targeted therapy and immunotherapy and uncovered tumor heterogeneity as a driver of resistance using innovative, patient-derived models.    

Image
MyungJu Ahn

Myung-Ju Ahn, M.D.

Professor of Hemato-Oncology at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul.
South Korea

Daniel C. Ihde Lectureship Award for Medical Oncology 

Myung-Ju Ahn is Professor of Hemato-Oncology at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul. She is a member of numerous research associations and societies, including the ISLAC, AACR, and ASCO and is currently Chief of the Executive Committee and Chairperson of Lung Cancer Disease Committee of the KCSG. She is the current president of the KSMO and was chairperson of the multidisciplinary Immuno-oncology Study Group (2017–2018). She is a board member for the KCA, KSMO and KALC, and is on the editorial board of Journal of Thoracic Oncology. 
    
Prof Ahn received her medical and doctoral degrees from Hanyang University College of Medicine, Seoul and completed her residency training at Hanyang University Hospital. She has held numerous research fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center, New York, and has authored over 250 cancer research publications. Her research interests include the development of predictive and prognostic markers for personalised lung cancer therapy. She has recently focused on early clinical trials for the development of drug discovery and reposition of targeted drugs and the development of a NSCLC genome atlas. Her accolades for her dedication to cancer research include Best Researcher Award, KMWA (2003); Best Researcher Award, KACO (2015); Boryoung Scientific Award, Korean Cancer Research Foundation (2018), and Highly Cited Researcher, Clavirate analytics (2019).
 

2019 Lectureship Award Winners

Image
Prof Faivre-Finn

Corinne Faivre-Finn, FRCR, MD, PhD

Honorary Consultant Oncologist and a Professor of Thoracic Radiation Oncology at The University of Manchester
United Kingdom

James D. Cox Lectureship Award for Radiation Oncology

Prof Faivre-Finn is an Honorary Consultant Oncologist and a Professor of Thoracic Radiation Oncology at The University of Manchester with an interest in lung cancer. She trained in Paris until 1998 and took a consultant post at The Christie in 2001. She was appointed as Professor of Thoracic Radiation Oncology at the University of Manchester in 2015. Prof Faivre-Finn is an active member of several national and international research committees including:

At the Christie Hospital in Manchester, Professor Corinne Faivre-Finn specialises in treating lung cancer. She is leading several important clinical trials, including CONVERT and LungART, to find out the best ways of combining radiotherapy and chemotherapy to treat the disease.

She is also testing more targeted ways of giving radiotherapy, called IMRT and SABR, to find out if they are effective for lung cancer patients who can’t have surgery.

Despite lung cancer being the most common cancer in the world, survival is poor and has changed little over the years. Clinical trials like the ones Professor Faivre-Finn is leading are essential to improve this situation and keep families together for longer.

Image
Roman Thomas

Roman K. Thomas, MD

The Department of Translational Genomics at the University of Cologne
Germany

Adi F. Gazdar Lectureship Award for Translational Science

Dr. Roman Thomas is a professor and chair of the Department of Translational Genomics at the University of Cologne. His lab's mission is to understand the impact of somatic genetic alterations in cancer cells on the highly complex regulatory network of signaling pathways.

Image
Giulia Veronesi

Giulia Veronesi, MD

Chief of the Robotic Thoracic Surgery Unit among the Division of Thoracic and General Surgery in Humanitas Research Hospital
Italy

Robert J. Ginsberg Lectureship Award for Surgery

She is a member of the committee on robotic cardio-thoracic surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and faculty member of European Society of Thoracic Surgery (ESTS). She is also a founding member of the Clinical Robotic Surgical Association (CRSA). She is active member of other international societies such as the International  Association on Study of Lung Cancer and the European Society of Medical Oncology.

Since 2004 she  has led one of the largest European lung cancer screening programs (the COSMOS 1 and 2 studies) using low dose Computer Thomography and molecular markers in high risk individuals.

Since 2006 she developed a pioneer program the robotic surgery program for thoracic disease and performed more than 250 robotic surgical procedures as first surgeon. Recently she become proctor of robotic surgery and trained thoracic surgeons in Geneve Huniversity Hospital and in different  italian centers.

She is Principal investigator of different NCI-supported trials focused mainly on lung cancer chemoprevention including the ongoing randomised double-blind phase II cancer prevention trial comparing daily aspirin with placebo in persons with subsolid nodules on LDCT. She designed and coordinated an ongoing Italian multicentric randomised trial on limited resection versus standard lobectomy for stage Ia non small cell lung cancer. She has been invited speaker at more than 60 national and international conferences as expert in the field of lung cancer prevention, lung cancer early detection and robotic minimally invasive thoracic surgery.

She is author and coauthor of more than 150 papers on international peer reviewed journals and authors of 8 book chapters. HI 22, IF 256.

Image
Caroline Dive

Caroline Dive, PhD

Heine H. Hansen Lectureship Award for Small Cell Lung Cancer

Caroline Dive is the current President of the European Association for Cancer Research (EACR), the Deputy Director of the Cancer Research UK (CRUK) Manchester Institute, the Director of the CRUK MI Biomarker Centre, as well as a Professor of Cancer Pharmacology at the University of Manchester in England.

Education

  • PhD, Experimental Cancer Therapeutics, MRC Clinical Oncology Experimental Radiotherapeutics Unit, Cambridge
  • BPharm, The School of Pharmacy, University of London

 

Image
Kahren M. White

Kahren M. White

Occupational Therapist
Australia

IASLC Lectureship Award for Nursing and Allied Health Professionals

Kahren White is an occupational therapist with 20 years clinical experience in oncology and palliative care. For the last 12 years she has focused on occupational therapy interventions for people living with thoracic malignancies, also researching and publishing in the area of breathlessness.
Kahren works at the Cancer Institute NSW in the area of cancer system improvement, as well as in her own private medico legal occupational therapy practice working with people with asbestos related diseases.

Image
Emily Stone

Emily Stone, MD

Consultant Respiratory Physician and Acting Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital
Australia

IASLC Lectureship Award for Tobacco Control and Smoking Cessation

Emily Stone is Chair of the IASLC Tobacco Control and Smoking Cessation Committee and a member of the TSANZ ENDS working group. Dr. Emily Stone is a Consultant Respiratory Physician and Acting Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital in Sydney. She is a conjoint Senior Lecturer at the University of New South Wales and the Chair of the St Vincent’s Hospital Lung Cancer Multidisciplinary Team (MDT). Her chief clinical and research interests are in the fields of lung cancer screening, multidisciplinary team care and tobacco control. She trained in respiratory medicine in Australia and is finalising doctoral studies in clinical data science in multidisciplinary team care via the University of Sydney. She is the NSW Principal Investigator for the International Lung Screen Trial (ILST) investigating low dose CT screening for lung cancer in Australia and internationally. Committee memberships include IASLC Tobacco Control and Smoking Cessation Committee (immediate past chair), member of the Cancer Council Australia Working Party for Clinical Practice Guidelines in Lung Cancer, member of the TSANZ ENDS/ENNDS Position Paper Working Party and Head of the Lung Cancer Assembly of the Asia-Pacific Society of Respirology.

Image
Daniel Tan

Daniel Tan, MD

Senior Consultant at the Division of Medical Oncology at National Cancer Centre Singapore (NCCS)
Singapore

Daniel C. Ihde Lectureship Award for Medical Oncology

Dr. Tan is a Senior Consultant at the Division of Medical Oncology at National Cancer Centre Singapore (NCCS) and a senior clinician-scientist at Genome Institute of Singapore.  His main area of interest is in thoracic, head and neck malignancies and drug development. He currently leads the Experimental Cancer Therapeutic Unit (ECRU) at NCCS, and has been instrumental to growing it to one of the largest phase I unit in Asia, running up approximately 30 -40 trials at any one time. He is also the Principal Investigator of the Cancer Therapeutics Research Laboratory at NCCS focused on developing representative patient- derived preclinical models to gain insights to drug response and resistant, complementing his role as the principles investigator for multiple biomarker-driven early phase clinical trials including first-in-human studies. He is the principal investigator for the National Medical Research Council Lung Cancer Large Collaborative Grant (2019-2023), and Chairs the Asian Thoracic Oncology Research Group, the latter set up as a platform to coordinate translational research and clinical trials in the region.

Dr. Tan’s research interests include rational application of “omics” technologies to unravel drug resistance in cancer therapeutics and accelerating the development of novel agents and biomarkers in the clinic. His research has been recognised through multiple local and international awards, including European Society of Medical Oncology Congress Travel Award, American Society of Clinical Oncology (ASCO) Merit Awards, ASCO Young Investigator Award as well as most recently being awarded the IASLC Daniel C. Idhe Lectureship Award in 2019, the latter in recognition of his work in the field of medical oncology and extensive contributions to the lung cancer arena. Dr Tan also holds a SingHealth GCEO Outstanding Clinician-Researcher Award and a National Medical Research Council Clinician-Scientist Award. He has published widely in journals including Nature, Nature Medicine, The New England Journal of Medicine, The Lancet, The Lancet Oncology and Journal of Clinical Oncology. Dr Tan is the past Chair of the Education Committee of the International Association for Study of Lung Cancer (IASLC) and has participated in the organising scientific committees and faculty member for multiple international conferences including WCLC, ESMO and ASCO. In ESMO 2021, he is the track chair for translational research. He has been active in developing educational resources to enhance quality of lung cancer care globally and is currently involved in The Lancet Commission on Lung Cancer. He serves as Associate Editor for the Journal of Thoracic Oncology and is the conference chair for the World Conference in Lung Cancer, the flagship and largest interdisciplinary conference of the IASLC.

Image
Paula A. Ugalde , MD

Paula A. Ugalde , MD

Director Oncology Research Program , Institut Universitaire de Cardiologie et de Pneumologie de Québec (Hôpital Laval)
Canada

Clifton F. Mountain Lectureship Award for Staging

Director Oncology Research Program , Institut Universitaire de Cardiologie et de Pneumologie de Québec (Hôpital Laval)

Image
Raja M. Flores, MD

Raja M. Flores, MD

Chairman for the Department of Thoracic Surgery at The Mount Sinai Medical Center
United States

Tsuguo Naruke Lectureship Award for Surgery

Considered a leading expert in the study and treatment of malignant pleural mesothelioma, Dr. Raja M. Flores is Chairman for the Department of Thoracic Surgery at The Mount Sinai Medical Center in New York. In addition to his medical degree, Dr. Flores also completed a clinical effectiveness program at Harvard’s School of Public Health and received an M.S. in biostatistics from Columbia University.

Certified by the American Board of Surgery and the American Board of Thoracic Surgery, Flores has served as the clinical assistant professor of cardiothoracic surgery at Cornell University Medical College, New York, and assistant professor of cardiothoracic surgery at the same institution. In addition to speaking English, Dr. Flores is fluent in both Spanish and Arabic, allowing him to more easily serve the diverse population of the New York City metropolitan area.

As a researcher, Dr. Flores has participated in and led many clinical trials, including several involving the study and treatment of malignant mesothelioma. Recent trials include a large study that involved the use of neoadjuvant gemcitabine and cisplatin followed by extrapleural pneumonectomy and high dose radiation for the treatment of malignant mesothelioma patients, and another which examined the use of neoadjuvant Alimta/cisplatin, extrapleural pneumonectomy, and high dose radiation to treat mesothelioma.

Main Speciality: Thoracic Surgery

Other Interests & Specialties: Malignant pleural mesothelioma, lung cancer screening, thoracoscopy, VATS lobectomy, intraoperative chemotherapy, tracheal, carinal, esophageal surgery, neoadjuvant gemcitabine and cisplatin, extrapleural pneumonectomy, neoadjuvant Alimta/cisplatin and pleurectomy decortication.

Certifications, Awards & Accolades: Merit awards from American Association for Thoracic Surgery (AATS), The Society of Thoracic Surgeons (STS), General Thoracic Surgical Club, Cardiothoracic Surgery Network, European Society of Thoracic Surgeons (ESTS) and the International Society for Minimally Invasive Cardiothoracic Surgery

Education & Experience:

  • Medical Degree from Albert Einstein College of Medicine
  • Residency at Columbia-Presbyterian Medical Center
  • Fellowship at Brigham and Women’s Hospital in Boston/Dana Farber Cancer Institute